Biomarker bioanalysis in oncology drug development and personalized medicine

Technological advancement and the discovery of various biomarkers have made personalized/precision medicine a reality. Biomarkers are measurable indicators of biological processes and can be used to diagnose cancer, determine prognosis and monitor response to therapy. In this precision oncology era, more and more clinical trials are now driven by biomarkers, with an overarching objective to optimize and personalize disease management. The inclusion of companion biomarkers – biomarkers that are used to prospectively predict a patient’s response to a therapy – has become mandatory in all new drug trials that are conducted for targeted therapies in the oncological field. By identifying specific biomarkers, researchers can develop more effective treatments that are tailored to individual patients, revolutionizing cancer treatment and improving patient outcomes.

This feature was produced in association with Frontage Laboratories, Inc.